Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ALDX
ALDX logo

ALDX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Aldeyra Therapeutics Inc (ALDX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.950
1 Day change
6.56%
52 Week Range
6.170
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ALDX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The stock has some short-term stabilization, but the broader picture is still driven by FDA setbacks, weak analyst sentiment, and extremely speculative options activity. I would not buy now; I would hold off until there is clearer fundamental progress or a stronger technical breakout.

Technical Analysis

The stock is trading near 1.73, just above the prior close of 1.71, with a modest gain and no strong trend confirmation. MACD is slightly positive but contracting, RSI_6 is neutral at 50.6, and moving averages are converging, which points to a sideways and indecisive trend rather than a confirmed uptrend. Key levels show pivot resistance at 1.754 with resistance at 1.901 and 1.992, while support sits at 1.607 and 1.516. In short, the chart does not show a strong buy setup right now. The stock trend model also suggests only modest near-term upside, with a 50% chance of -1.45% next day, 0.08% next week, and 2.85% next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Options sentiment is mixed and somewhat distorted by speculative activity. The open interest put-call ratio of 0.37 suggests more call open interest than puts, which is usually bullish on balance. However, the option volume put-call ratio of 93.5 is extremely high and points to heavy put volume relative to calls, which signals active bearish or hedging demand. Implied volatility is extremely elevated at 494.77 with IV percentile at 99.21, showing the market is pricing in very large uncertainty. Overall, options do not support a clean bullish conviction.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
8

Positive Catalysts

  • Aldeyra recently appointed Darlene Deptula-Hicks to its board, which adds experienced biotechnology leadership and could improve strategic execution. The stock also has a small recent price uptick and a neutral-to-slightly positive MACD reading, suggesting some short-term stabilization. If the company makes meaningful progress on reproxalap or regains regulatory confidence, sentiment could improve quickly from current depressed levels.

Neutral/Negative Catalysts

  • The most important negative catalyst is the FDA complete response letter tied to reproxalap for dry eye disease, which led to a major analyst downgrade and sharply reduced the perceived probability of success. Analyst price target was cut from $10 to $2, which is a severe reset in expectations. The business currently lacks a strong financial snapshot in the provided data, there is no valuation support, and both hedge funds and insiders are neutral with no meaningful buying trend. Options activity also reflects very high uncertainty and heavy put volume. There is no supportive congress trading data or influential figure activity to offset this.

Financial Performance

No usable latest-quarter financial snapshot was provided, so there is no confirmed revenue or earnings growth trend to support a long-term buy case. The absence of current quarterly financial detail makes it difficult to justify the stock for a beginner investor seeking clearer fundamentals.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Sentiment has turned bearish. On 2026-03-18, H.C. Wainwright downgraded Aldeyra to Neutral from Buy and slashed the price target from $10 to $2 after the FDA complete response letter. This is a major negative shift in Wall Street expectations. The pros view now appears cautious to bearish: some residual upside exists if the pipeline recovers, but the cons dominate because regulatory risk and probability-of-success reassessment have materially weakened the investment case.

Wall Street analysts forecast ALDX stock price to rise
2 Analyst Rating
Wall Street analysts forecast ALDX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.830
sliders
Low
9
Averages
9.5
High
10
Current: 1.830
sliders
Low
9
Averages
9.5
High
10
H.C. Wainwright
Matthew Caufield
Buy -> Neutral
downgrade
$10 -> $2
AI Analysis
2026-03-18
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$10 -> $2
AI Analysis
2026-03-18
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Matthew Caufield downgraded Aldeyra to Neutral from Buy with a price target of $2, down from $10, after the company received a complete response letter from the FDA related to reproxalap for the topical treatment of the signs and symptoms of dry eye disease. The firm reduced its probability of success for reproxalap from 75% to 40% and downgraded Aldeyra.

People Also Watch